Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 1,694 trials

XEN1101 for Primary Generalized Tonic-Clonic Seizures

We are studying whether XEN1101 can help reduce the frequency of seizures in people with Primary Generalized Tonic-Clonic Seizures compared to a placebo. This trial aims to understand its safety and impact on seizure control.

Generalized Tonic-Clonic SeizureConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Advanced Hepatobiliary Cancer: New Immunomodulators

We are studying new immunomodulators to see if they can improve treatment outcomes for patients with advanced hepatobiliary cancer. This includes testing their safety and effectiveness alone and with other cancer therapies.

Bile Duct CancerGallbladder CancerHepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

THC Oil for Chronic Neuropathic Pain

We are studying the effects of THC 2% oil on pain relief in patients with chronic neuropathic pain. The trial will also explore how different patient traits may influence the treatment's effectiveness and safety.

Neuropathic Pain≤3 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteInternal MedicineNeurology

Breast Cancer Treatment: Tucatinib and Capecitabine

We are studying a combination of tucatinib, capecitabine, and trastuzumab for patients with HER2-positive breast cancer that has spread to the meninges. The goal is to see if this treatment improves survival and quality of life.

HER2-Amplified Metastatic Breast Cancer with Leptomeningeal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Prostate Cancer: New Treatment Approach with Hormone Therapy

We are studying whether adding short-term hormone therapy to a targeted treatment helps men with recurrent prostate cancer and a limited number of metastases live longer and improve their quality of life.

Oligorecurrent Hormone-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncologyUrology

CAR-T-Cell Treatment for High-Risk Mantle Cell Lymphoma

We are exploring a new CAR-T-cell therapy for patients with untreated high-risk Mantle Cell Lymphoma. The study compares this new approach to the standard treatment to see which is more effective and safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Advanced Colorectal Cancer: Cetuximab with Encorafenib and Binimetinib

We are studying a combination of three medications for patients with BRAF V600E mutated advanced colorectal cancer. The goal is to see if this treatment can help make surgery possible and improve overall health outcomes.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: ADT with Darolutamide

We are studying whether adding darolutamide to standard hormone therapy helps frail men with newly diagnosed metastatic prostate cancer live longer and feel better. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Prostate Cancer1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncology

Advanced Cutaneous Squamous Cell Carcinoma: INCB099280 Study

We are evaluating a new medication for people with advanced cutaneous squamous cell carcinoma to see how safe it is and if it may help improve their condition.

Recurrent and Metastatic Skin Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Acute Myeloid Leukemia: Gilteritinib vs. Midostaurin

We are studying whether gilteritinib works better than midostaurin for patients with AML or MDS with a FLT3 mutation. This trial looks at treatment effectiveness and safety during chemotherapy and maintenance therapy.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2)1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Atrial Fibrillation: Warfarin Study for Dialysis Patients

We are investigating the safety and effectiveness of warfarin in patients with atrial fibrillation who are on dialysis. This study aims to understand how this medication impacts their health.

Atrial FibrillationEnd-Stage Renal Disease>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyNephrology

Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyPediatrics

Late-onset Pompe Disease: Cipaglucosidase Alfa and Miglustat Study

We are evaluating the safety and effectiveness of a new treatment for children with late-onset Pompe disease. This study aims to understand how well the medications work together and their effects on young patients.

Late-onset Pompe Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyHematologyPediatrics

Lymphoma Treatment Study: Zanubrutinib vs. Lenalidomide

We are comparing the effectiveness of zanubrutinib combined with anti-CD20 antibodies against lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma. This study aims to find out which treatment works better and is safer.

Marginal Zone LymphomaFollicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Multiple Sclerosis: BIIB091 Treatment Study

We are studying the safety of BIIB091 alone and with Diroximel Fumarate in adults with relapsing forms of multiple sclerosis. The goal is to see how these treatments affect brain inflammation.

Relapsing Multiple Sclerosis1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementNeurology

Ovarian Cancer: NiraParib Maintenance Study

We are studying whether three cycles of chemotherapy followed by the drug niraparib is as effective as six cycles for patients with advanced ovarian cancer. This trial focuses on those who have had their tumors completely removed and are HRD-positive.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Asthma Treatment: Povorcitinib Study

We are evaluating a new medication for adults with moderate to severe asthma that isn't well controlled. The study aims to see if it improves lung function and reduces asthma attacks.

Asthma3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology